Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Claudia Pitotti"'
Autor:
Giorgio Lorenzo Colombo, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Maria Chiara Valentino, Giacomo Matteo Bruno, Claudia Pitotti, Francesco Menzella
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 13 (2019)
Background: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an i
Externí odkaz:
https://doaj.org/article/e3ac39563b434878ac7ec8c489d6438a
Publikováno v:
Global & Regional Health Technology Assessment, Vol 2018 (2018)
Purpose: We aimed to estimate the 3-year budget impact of replacing salmeterol/fluticasone with indacaterol/glycopyrronium for the treatment of chronic obstructive pulmonary disease patients in Italy. Methods: The budget impact model included patient
Externí odkaz:
https://doaj.org/article/53c6353838134e028f57d62cab883a4e
Publikováno v:
Global & Regional Health Technology Assessment, Vol 5, Iss 1 (2018)
Externí odkaz:
https://doaj.org/article/40572cd599df4da3b7c256c68d0fb67a
Autor:
Carlo Cerra, Mirosa Dellagiovanna, Simona Migliazza, Roberto Tettamanti, Corrado Zuliani, Roberto Ravasio, Delia Colombo, Claudia Pitotti, Emanuela Zagni
Publikováno v:
Global & Regional Health Technology Assessment, Vol 3, Iss 3 (2016)
Externí odkaz:
https://doaj.org/article/622d44c942504a3aafafbc2321c8e8bc
Autor:
Claudia Pitotti, Domenico Mantoan, Daniela Ritrovato, Giovanna Scroccaro, Luca Degli Esposti, Diego Sangiorgi, Valentina Perrone, Anna Michela Menti, Margherita Andretta, Simona Aurora Bellometti
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 20:499-505
Objectives: Aim of the study was to describe the use and pharmacoutilization profiles of recommended drugs for HF patients, hospital re-admission rates, mortality rates and determine healthcare res...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a781eeb7c1e2bb32c71e35df449c6a91
https://doi.org/10.1080/14737167.2020.1718494
https://doi.org/10.1080/14737167.2020.1718494
Autor:
Claudia Pitotti, Chiara Martinotti, Giorgio Walter Canonica, Paola Rogliani, Sergio Di Matteo, Giorgio Colombo, GM Bruno, Pierachille Santus
Publikováno v:
Risk Management and Healthcare Policy. 13:43-53
Introduction Inadequately controlled severe asthma patients require additional therapy accounting for significant clinical and economic burden. Our analysis aims to determine the cost-effectiveness of omalizumab in the management of severe allergic a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12e11449858e80f4476d8c49b8497956
https://doi.org/10.2147/rmhp.s211321
https://doi.org/10.2147/rmhp.s211321
Autor:
Daniela Ritrovato, Paolo Cortesi, Lucia Sara D'Angiolella, Michele Senni, Lorenzo G. Mantovani, Claudia Pitotti
Publikováno v:
European Journal of Heart Failure. 19:1551-1553
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57b1a80d647d2a1a77316c59624a7a43
https://doi.org/10.1002/ejhf.919
https://doi.org/10.1002/ejhf.919
Publikováno v:
Airway Pharmacology and Treatment.
Introduction: Poorly controlled allergic asthma is associated with increased medical resource utilisation (MRU). PROXIMA study demonstrated effects of omalizumab on asthma control in Italian patients with severe allergic asthma (SAA). Here, we report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee46c41e865853d31a8c90a59ffbc175
https://doi.org/10.1183/1393003.congress-2017.pa3961
https://doi.org/10.1183/1393003.congress-2017.pa3961
Autor:
Dorothy L. Keininger, Claudia Pitotti, Elsa Sauvage, M. Reza Maleki-Yazdi, J Carrasco, Sara Chehab, Jean-Bernard Gruenberger, David Price, Mathieu Molimard
Publikováno v:
Applied health economics and health policy. 14(5)
The objective of this study was to assess the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in patients with moderate-to-severe chronic obstructive pulmonary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bb2b0271a3591e46940b82b7f7b3f9e
https://pubmed.ncbi.nlm.nih.gov/27516088
https://pubmed.ncbi.nlm.nih.gov/27516088